RevMed’s newly approved Rasonque could ‘hold up’ in non-small cell lung cancer

Data ReadoutpositiveRasonquePositive

AI Analysis

Summary

RevMed's approved drug Rasonque demonstrated a 42% overall response rate and 16-month overall survival in a RAS mutant NSCLC subgroup from an earlier trial, supporting the company's ongoing Phase 3 study in this patient population.

Clinical Trial Data

Phase

Phase 3

Outcome Details

42% overall response rate and 16 months overall survival in RAS mutant NSCLC subgroup from earlier trial

Importance:6/10

Sentiment:

0.70

oncologyNSCLCRAS mutationclinical dataapproval

Related Companies

$RVMD

Read the original article

Published by BioSpace on September 3, 2026 2:06 PM

Read Original